Takeda Pharmaceutical's first female CEO appears: plans to restore growth within three years, releasing three blockbuster drugs in the next 12 months.

According to the financial news app Securities Times, Julie Kim, the newly appointed CEO of Takeda Pharmaceuticals (TAK.US), stated that the company is preparing to launch a series of new products and aims to resume growth within two to three years. At her first press conference as CEO this week, Kim stated that the company's goal is to achieve a minimum of 5% return on equity during this period.